Pfizer Comprehensive Income 2010-2024 | PFE
Pfizer comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Pfizer comprehensive income for the quarter ending September 30, 2024 was $-7.816B, a 3.53% decline year-over-year.
- Pfizer comprehensive income for 2023 was $-7.961B, a 4.13% decline from 2022.
- Pfizer comprehensive income for 2022 was $-8.304B, a 40.82% increase from 2021.
- Pfizer comprehensive income for 2021 was $-5.897B, a 11.05% increase from 2020.
Pfizer Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$-7,961 |
| 2022 |
$-8,304 |
| 2021 |
$-5,897 |
| 2020 |
$-5,310 |
| 2019 |
$-11,640 |
| 2018 |
$-11,275 |
| 2017 |
$-9,321 |
| 2016 |
$-11,036 |
| 2015 |
$-9,522 |
| 2014 |
$-7,316 |
| 2013 |
$-3,271 |
| 2012 |
$-5,953 |
| 2011 |
$-4,129 |
| 2010 |
$-3,440 |
| 2009 |
$552 |
Pfizer Quarterly Comprehensive Income
(Millions of US $) |
| 2024-06-30 |
$-7,816 |
| 2024-03-31 |
$-7,758 |
| 2023-12-31 |
$-7,961 |
| 2023-09-30 |
$-7,966 |
| 2023-06-30 |
$-8,102 |
| 2023-03-31 |
$-8,289 |
| 2022-12-31 |
$-8,304 |
| 2022-09-30 |
$-8,225 |
| 2022-06-30 |
$-7,119 |
| 2022-03-31 |
$-6,157 |
| 2021-12-31 |
$-5,897 |
| 2021-09-30 |
$-5,649 |
| 2021-06-30 |
$-4,758 |
| 2021-03-31 |
$-4,664 |
| 2020-12-31 |
$-5,310 |
| 2020-09-30 |
$-12,676 |
| 2020-06-30 |
$-13,246 |
| 2020-03-31 |
$-13,131 |
| 2019-12-31 |
$-11,640 |
| 2019-09-30 |
$-11,801 |
| 2019-06-30 |
$-11,535 |
| 2019-03-31 |
$-10,923 |
| 2018-12-31 |
$-11,275 |
| 2018-09-30 |
$-10,417 |
| 2018-06-30 |
$-10,003 |
| 2018-03-31 |
$-9,402 |
| 2017-12-31 |
$-9,321 |
| 2017-09-30 |
$-9,164 |
| 2017-06-30 |
$-10,181 |
| 2017-03-31 |
$-10,594 |
| 2016-12-31 |
$-11,036 |
| 2016-09-30 |
$-8,214 |
| 2016-06-30 |
$-8,891 |
| 2016-03-31 |
$-9,520 |
| 2015-12-31 |
$-9,522 |
| 2015-09-30 |
$-9,170 |
| 2015-06-30 |
$-8,521 |
| 2015-03-31 |
$-8,557 |
| 2014-12-31 |
$-7,316 |
| 2014-09-30 |
$-3,467 |
| 2014-06-30 |
$-3,152 |
| 2014-03-31 |
$-3,390 |
| 2013-12-31 |
$-3,271 |
| 2013-09-30 |
$-6,383 |
| 2013-06-30 |
$-6,465 |
| 2013-03-31 |
$-6,155 |
| 2012-12-31 |
$-5,953 |
| 2012-09-30 |
$-5,653 |
| 2012-06-30 |
$-6,008 |
| 2012-03-31 |
$-3,622 |
| 2011-12-31 |
$-4,129 |
| 2011-09-30 |
$-1,211 |
| 2011-06-30 |
$-952 |
| 2011-03-31 |
$-2,056 |
| 2010-12-31 |
$-3,440 |
| 2010-09-30 |
$-3,698 |
| 2010-06-30 |
$-4,407 |
| 2010-03-31 |
$-1,941 |
| 2009-12-31 |
$552 |
| 2009-09-30 |
$-1,896 |
| 2009-06-30 |
$-2,079 |
| 2009-03-31 |
$-4,673 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$148.702B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
